

Platelets and Blood Cells

The polymorphism of platelet membrane integrin $\alpha_2\beta_1$ (α_2807TT) is associated with premature onset of fetal loss

Andrea Gerhardt¹, Rüdiger E. Scharf¹, Barbara Mikat-Drozdowski², Jan S. Krüssel², Hans G. Bender², Rainer B. Zotz¹

¹Department of Hemostasis and Transfusion Medicine, and ²Department of Obstetrics and Gynecology, Heinrich Heine University Medical Center, Düsseldorf, Germany

Summary

Inherited thrombophilia could increase susceptibility to adverse pregnancy outcomes such as fetal loss. We determined the G1691A mutation of the factor V gene (FVL), the G20210A mutation of the prothrombin gene, the C677T polymorphism of the methylenetetrahydrofolate-reductase (MTHFR) gene, the HPA-I polymorphism of the β_3 subunit of the platelet integrin $\alpha_{IIb}\beta_3$ and the C807T polymorphism of the α_2 subunit of integrin $\alpha_2\beta_1$ in 104 women with fetal loss and 277 normal women. In a subgroup analysis of women with recurrent early fetal loss ($n=34$), the prevalence of the genetic markers did not differ significantly between the women with early fetal loss and the normal women. However, in this subgroup of patients the onset of fetal loss was significantly earlier in women with the α_2807TT genotype (7.1 ± 1.9 vs. 8.8 ± 1.5 weeks, $p=0.001$). No such sig-

nificant difference was observed in carriers of the other genetic markers. In the subgroup analysis of women with late fetal loss ($n=70$), only the prevalence of heterozygous FVL was significantly associated with late fetal loss (odds ratio 3.2, $p=0.002$). There was no significant association of any genetic risk factor with premature fetal loss in the subgroup analysis of women with at least one late miscarriage. This study demonstrates a significant association of the α_2807TT genotype of the platelet membrane integrin $\alpha_2\beta_1$ with premature onset of early fetal loss. It appears that this risk factor does not induce the pathomechanism, but modulates the course of fetal loss. Furthermore, our study confirms the association of FVL with late fetal loss.

Keywords

Fetal loss, platelet receptor polymorphisms, HPA-I/PIA, $\alpha_{IIb}\beta_3$, glycoprotein IIb-IIIa, α_2807TT genotype, $\alpha_2\beta_1$, glycoprotein Ia-IIa

Thromb Haemost 2005; 93: 124-9

Introduction

In pregnancy, a successful outcome is highly dependent on appropriate placental development and sustained placental function. These processes, in turn, require the formation of an adequate feto-maternal circulatory system (1). Obstetrical complications such as recurrent miscarriage, stillbirth, severe pre-eclampsia, abruptio placentae, and fetal growth retardation are associated with abnormal placental vasculature and inadequate placental maternal-fetal circulation (2–7).

The hemostatic pathways are intimately involved in ovulation, implantation and placentation (8). Pregnancy per se is associated with a hypercoagulable state (8). Although recurrent fetal loss is a heterogeneous condition and no single abnormality

can account for all cases of fetal loss, the hypothesis has been developed that many cases of miscarriage, both early and late, are caused by an exaggerated maternal hemostatic response leading to thrombosis of the uteroplacental vasculature and subsequent fetal loss (1, 9–14).

Established thrombophilic risk factors, most of them are well known risk determinants of venous thrombosis, include the G1691A mutation of the factor V gene (factor V Leiden), the G20210A mutation of the prothrombin-gene, hyperhomocysteinemia and deficiencies of antithrombin, protein C and protein S. The degree of the association between thrombophilia and fetal loss varies in the published studies, related to type of fetal loss and the type of thrombophilia (14). The association between homozygosity for the C677T polymorphism of the methylene-

Correspondence to:
Rainer B. Zotz, M.D.
Institut für Hämostaseologie und Transfusionsmedizin
Heinrich-Heine-Universität
Moorenstraße 5
D-40225 Düsseldorf
Germany
Tel.: +49 211 811 7237, Fax: +49 211 811 6221
E-mail: zotz@med.uni-duesseldorf.de

Received July 6, 2004
Accepted after resubmission September 20, 2004

Financial support:
Supported by an institutional grant (# 9772153) of the Faculty of Medicine, Heinrich Heine University, Düsseldorf

Prepublished online November 8, 2004 DOI: 10.1160/TH04-07-0411

tetrahydrofolate-reductase (MTHFR)-gene and venous thrombosis or fetal loss is controversial (14).

In the case of a vascular alteration primarily located in the arterial system, a risk factor of arterial thrombogenicity may be of importance. Platelets play a pivotal role in the pathogenesis of arterial thrombosis, which has been well documented for acute coronary syndromes and cerebrovascular events.

As shown in preliminary studies, two platelet receptor genotypes, the HPA 1-b allele of the β_3 subunit of the essential platelet integrin $\alpha_{IIb}\beta_3$, also known as glycoprotein IIb-IIIa, and the 807TT genotype of the α_2 subunit of integrin $\alpha_2\beta_1$, also known as glycoprotein Ia-IIa, are risk factors for increased platelet thrombogenicity (15–21). In accordance with this observation, these genetic variants may lead to thrombotic occlusion in the presence of a predisposing vascular alteration resulting in premature fetal loss.

We used a case-control design to assess hereditary risk factors of venous and arterial thrombosis as risk determinants for recurrent fetal loss and a case-only design to assess these risk factors as determinants for premature onset of fetal loss.

Materials and methods

Subjects

We retrospectively studied 104 consecutive women who had recurrent fetal loss without known cause, who were referred for thrombophilia screening to the Düsseldorf University Medical Center between January 1999 and July 2003. To avoid a referral bias, all women with prior evaluation of genetic risk factors were excluded. Women were also excluded if they had the antiphospholipid-syndrome. Inclusion criteria were either recurrent early fetal loss (three or more consecutive fetal losses at < 12 weeks gestation and no late fetal loss, $n=34$), or at least one late fetal loss (≥ 12 weeks gestation, $n=70$) according to previously published classifications (11).

Only women with post-embryonic loss after ultrasonic disappearance of fetal pulse from the intrauterine fetal pole were included in the study. Documented first trimester preclinical and blighted ovum abortions, as well as fetal losses that were the result of documented fetal malformation or the result of an infectious complication, were excluded. None of the women received an antithrombotic prophylactic therapy (e.g. low molecular weight heparin) or an antiplatelet agent during the pregnancy complicated by fetal loss.

The women enrolled with recurrent fetal loss had no previous history of venous or arterial thromboembolic disease, diabetes mellitus, chronic hypertension, thyroid dysfunction, systemic lupus erythematosus, intrauterine growth retardation, pregnancy-induced hypertension, or preeclampsia. They all had a detailed investigation which was negative for potential causes of fetal demise including fasting glucose, basal FSH, LH and estradiol levels on day 3 of a natural cycle, TSH and prolactin levels and antinuclear factor.

In addition, transvaginal scanning was performed to verify ovarian morphology. Women with three or more first trimester or one or more second or third trimester pregnancy losses underwent a hysterosalpingography and/or hysteroscopy to confirm

uterine cavity normalcy, and both partners were also investigated for chromosomal aberrations.

As control subjects, 277 normal women with at least one previous pregnancy, no previous fetal loss or late pregnancy complications, and no history of previous arterial or venous thromboembolism were recruited by the Heinrich Heine University Blood Donation Center. The normal women were from the same geographic region as the women with recurrent fetal loss, but were unrelated to them.

Personal histories were obtained from all women with the use of a standardized questionnaire. The study was approved by the ethical committee of the Faculty of Medicine, Heinrich Heine University, Düsseldorf, and written informed consent was given by all women.

Laboratory tests

Genomic DNA was extracted from peripheral blood leukocytes according to standard protocols using the Chelex system (BIO-RAD, München, Germany) or Qiagen system (Qiagen, Hilden, Germany). The presence or absence of factor V Leiden and the G20210A mutation in the prothrombin gene were identified using an allele-specific restriction-enzyme analysis as reported (21, 22). Analysis for the presence of the MTHFR C677T polymorphism was performed by the method described by Frosst et al. (23). Determination of the HPA-1 polymorphism of the β_3 subunit of $\alpha_{IIb}\beta_3$ and the C807T polymorphism of the α_2 subunit of integrin $\alpha_2\beta_1$ was performed as previously described (24, 25).

The activities of plasma protein C and protein S were measured by a functional clotting assay (Instrumentation Laboratory, Milano, Italy), and total protein S antigen and free protein S antigen by an ELISA Kit (Diagnostic International, Schriesheim, Germany). Antithrombin activity was measured with the use of Berichrom (Dade Behring, Liederbach, Germany).

Statistical analysis

The association of genetic variants with an increased risk for fetal loss was evaluated in a case-control design. Differences in proportions were tested by the Fisher exact test and relative risk was estimated by the odds ratio. The results of continuous variables were calculated as means \pm standard deviation (SD). Continuous variables were compared by Wilcoxon two sample exact test. The analyses were performed in subgroups of women with early and late fetal losses.

The association of genetic variants with premature onset of fetal loss was evaluated in two ways. First, the weeks of gestation at onset of the earliest fetal loss were analyzed using the Wilcoxon two sample exact test and a multivariate regression analysis based on the Cox proportional hazards model to identify independent predictors of premature fetal loss. Variables included in the analyses fulfilled the proportional-hazards assumption, since the results of tests of these variables for nonproportional hazards were not significant. Since only patients with fetal loss were evaluated in this model, no individuals were censored and the proportional hazards model represents a multivariate analysis evaluating premature onset of fetal loss and not an increased risk of fetal loss.

Second, the complete data of *all* early fetal losses (n=132) in the subgroup of women (n=34) with early fetal losses and *all* late fetal losses (n=91) in the subgroup of women with late fetal loss (n=70) over time were analyzed regarding the weeks of gestation at fetal loss using a mixed model with unequally spaced repeated measurements (26). In this analysis, each pregnancy represents a new measurement. This model allows a longitudinal analysis of the influence of a between-subjects factor (e.g. genetic variant) on the week of fetal loss, the influence of a within-subjects factor (number of fetal losses) on the week of fetal loss, and the interaction of the genetic variant and number of fetal losses representing a change of risk factor-dependent differences over time (number of fetal losses).

Subjects with HPA-1a/1b or HPA-1b/1b genotypes were classified as HPA-1b-positive, those with HPA-1a/1a as HPA-1b-negative (dominant model). In the C807T polymorphism, the 807TT genotype was compared with the 807CC+CT genotypes (recessive model). This classification is based on the results of previous functional and clinical studies (16). P values of less than 0.05 were considered to be significant. All confidence intervals were calculated at the 95 percent level. All statistical analyses were performed with SAS software (version 8.2, SAS Institute Inc., Cary, North Carolina).

Results

Study patients

The study population comprised 34 women with recurrent early fetal loss (three or more consecutive miscarriages at < 12 weeks gestation and no late fetal loss), and 70 women with late fetal loss (at least one late miscarriage at \geq 12 weeks gestation). The median age of the women with recurrent fetal loss was 35.1 years \pm 7.7 vs. 33.6 years \pm 12.4 of the normal women. In total, 104 women with recurrent fetal loss had 262 previous pregnancy

losses (mean 2.5, range 1 to 7). The number of fetal losses among the 34 women with early fetal loss was 132 (mean 3.9, range 3–7); of these women, 17 (50 %) had at least one successful pregnancy. The number of fetal losses among the 70 women with late fetal loss was 130 with 91 late fetal losses (mean 1.30, range 1 to 4) and 39 early fetal losses (mean 1.3, range 1 to 2); of these women, 40 (61.4 %) had at least one successful pregnancy.

Risk association with recurrent fetal loss using a case-control design

The prevalence of heterozygous factor V Leiden was significantly higher among the women with recurrent fetal loss (n=104) than among the normal women (Table 1). In contrast, no significant difference in the prevalences of the G20210A prothrombin gene mutation and of the MTHFR 677TT genotype as well as the prevalences of HPA-1b and α_2 807TT genotype were found in women with recurrent fetal loss and in normal women (Table 1). None of the women had a combined heterozygous or homozygous defect of the factor V Leiden or the G20210A prothrombin gene mutation and none of the women had a deficiency of antithrombin, protein C, or protein S.

To assess a possible difference between risk factors of early and late fetal loss, additional subgroup analyses in women with three or more consecutive miscarriages at < 12 weeks gestation and those with at least one late miscarriage at \geq 12 weeks gestation were performed.

Women with early fetal loss

In the subgroup analysis of women with three or more consecutive miscarriages at < 12 weeks gestation, the prevalence of the genetic markers did not differ significantly between the women with recurrent fetal loss (n=34) and the normal women (n=277) (Table 1).

Table 1: Risk association with recurrent fetal loss using a case-control design.

| Genetic Defect | Women With Recurrent Fetal Loss (n=104) | | Normal Women (n=277) | | P Value | Odds Ratio | 95% Confidence Interval |
|--|---|------------------------------|----------------------|------------------------------|---------|-------------|-------------------------|
| | % | (no. with defect/ total no.) | % | (no. with defect/ total no.) | | | |
| Factor V Leiden heterozygous | | | | | | | |
| All fetal losses (n=104) | 15.4 | 16/104 | 7.9 | 22/277 | 0.036 | 2.1 | (1.0-4.2) |
| Early fetal loss (n=34) | 2.9 | 1/34 | | | 0.49 | 0.4 | (0.1-2.7) |
| Late fetal loss (n=70) | 21.4 | 15/70 | | | 0.002 | 3.2 | (1.5-6.5) |
| Prothrombin G20210A heterozygous | | | | | | | |
| All fetal losses (n=104) | 1.9 | 2/104 | 2.2 | 6/277 | 1.0 | 0.89 | (0.2-4.5) |
| Early fetal loss (n=34) | - | - | | | - | - | - |
| Late fetal loss (n=70) | 2.9 | 2/70 | | | 0.67 | 1.3 | (0.3-6.7) |
| 677TT MTHFR genotype | | | | | | | |
| All fetal losses (n=104) | 13.5 | 14/104 | 10.1 | 28/277 | 0.36 | 1.4 | (0.7-2.7) |
| Early fetal loss (n=34) | 14.7 | 7/34 | | | 0.38 | 1.5 | (0.6-4.3) |
| Late fetal loss (n=70) | 12.9 | 9/70 | | | 0.52 | 1.3 | (0.6-2.9) |
| HPA – 1b- positive * | | | | | | | |
| All fetal losses (n=104) | 21.2 | 22/104 | 28.5 | 79/277 | 0.15 | 0.7 | (0.4-1.2) |
| Early fetal loss (n=34) | 20.6 | 7/34 | | | 0.42 | 0.7 | (0.3-1.6) |
| Late fetal loss (n=70) | 21.4 | 15/70 | | | 0.29 | 0.7 | (0.4-1.3) |
| $\alpha_2$807TT genotype | | | | | | | |
| All fetal losses (n=104) | 15.4 | 16/104 | 13.0 | 36/277 | 0.62 | 1.2 | (0.6-2.3) |
| Early fetal loss (n=34) | 14.7 | 5/34 | | | 0.79 | 1.2 | (0.4-3.2) |
| Late fetal loss (n=70) | 15.7 | 11/70 | | | 0.56 | 1.2 | (0.6-2.6) |

* Subjects with the HPA-1a/HPA-1a genotype were classified as HPA-1b-negative and subjects with the HPA-1a/HPA-1b genotype or HPA-1b/HPA-1b genotype were classified as HPA-1b-positive.

Table 2: Premature fetal loss in women with three and more early abortions according to genetic risk determinant (case-only design).

| Analysis Using Earliest Fetal Loss as Event Time in 34 Women | | | | | | | Analysis Using all Early Abortions (n=132) as Event Time in 34 Women | | | | | | |
|--|-------------------------|------------------|-------------------------|------------------|--|------------------------|--|------------------|-------------------------|------------------|------------------------------------|--|--|
| Genetic Defect | Genetic Marker Negative | | Genetic Marker Positive | | P Value Univariate (Wilcoxon Exact Test) | P Value Multivariate * | Genetic Marker Negative | | Genetic Marker Positive | | P Value (Mixed Model Multivariate) | | |
| | No. | Week of abortion | No. | Week of abortion | | | No. | Week of abortion | No. | Week of abortion | | | |
| | Mean ± SD | | Mean ± SD | | | | Mean ± SD | | Mean ± SD | | | | |
| Factor V Leiden heterozygous | 33 | 7.7 1.6 | 1 | 6.0 0 | 0.47 | 0.13 | 129 | 8.6 1.6 | 3 | 7.0 1.0 | 0.27 | | |
| Prothrombin G20210A heterozygous | 34 | 7.7 1.7 | - | - | - | - | 132 | 8.5 1.6 | - | - | - | | |
| 677TT MTHFR genotype | 29 | 7.9 1.6 | 5 | 6.6 1.5 | 0.13 | 0.14 | 114 | 8.6 1.5 | 18 | 7.9 2.1 | 0.18 | | |
| HPA – 1b- positive † | 27 | 7.8 1.7 | 7 | 7.1 1.5 | 0.36 | 0.82 | 109 | 8.6 1.6 | 23 | 8.1 1.6 | 0.75 | | |
| α ₂ 807TT genotype | 29 | 8.1 1.4 | 5 | 5.4 0.9 | 0.001 | <0.0001 | 111 | 8.8 1.5 | 21 | 7.1 1.9 | 0.001 | | |

* Multivariate analysis: including age, factor V Leiden, 677TT MTHFR genotype, HPA-1 genotype, and α₂807TT genotype.

† Subjects with the HPA-1a/HPA-1a genotype were classified as HPA-1b-negative and subjects with the HPA-1a/HPA-1b genotype or HPA-1b/HPA-1b genotype were classified as HPA-1b-positive.

Women with late fetal loss

In contrast, in the subgroup analysis of women with at least one late miscarriage (≥ 12 weeks gestation) (n=70), the prevalence of heterozygous factor V Leiden was significantly higher among the women with fetal loss than among the normal women (Table 1). No significant difference in the prevalences of the G20210A prothrombin gene mutation and of the MTHFR 677TT genotype as well as the prevalences of HPA-1b and α₂807TT genotype were found in women with late fetal loss and in normal women (Table 1).

Assessment of premature fetal loss using a case-only design

To assess an association of the different genotypes with premature fetal loss, a case-only design was used (Table 2).

Women with early fetal loss

In the subgroup analysis of women with early fetal loss (three or more consecutive miscarriages at < 12 weeks gestation), the onset of the earliest fetal loss was significantly earlier in women with the α₂807TT genotype (Wilcoxon exact test p=0.001). No such significant difference was observed in carriers of the other genetic markers (factor V Leiden, the G20210A prothrombin gene mutation, the MTHFR 677TT genotype, HPA-1b) (Table 2). These results were confirmed using the mixed model analysis for evaluation of all early fetal losses over time. The α₂807TT genotype was significantly associated with premature fetal loss using univariate and multivariate analysis (Table 2). There was no significant influence of the number of fetal losses and no significant interaction between any risk factor and the number of fetal losses on the week of fetal loss (Table 2).

Table 3: Premature fetal loss in women with at least one late fetal loss (± 12 weeks gestation) according to genetic risk determinant (case-only design).

| Analysis Using Earliest Fetal Loss as Event Time in 70 Women | | | | | | | Analysis Using all Late Abortions (n=91) as Event Time in 70 Women | | | | | | |
|--|-------------------------|------------------|-------------------------|------------------|--|------------------------|--|------------------|-------------------------|------------------|------------------------------------|--|--|
| Genetic Defect | Genetic Marker Negative | | Genetic Marker Positive | | P Value Univariate (Wilcoxon Exact Test) | P Value Multivariate * | Genetic Marker Negative | | Genetic Marker Positive | | P Value (Mixed Model Multivariate) | | |
| | No. | Week of abortion | No. | Week of abortion | | | No. | Week of abortion | No. | Week of abortion | | | |
| | Mean +- SD | | Mean +- SD | | | | Mean +- SD | | Mean +- SD | | | | |
| Factor V Leiden heterozygous | 55 | 18.9 8.7 | 15 | 16.8 5.7 | 0.36 | 0.52 | 72 | 18.6 8.7 | 19 | 16.6 5.4 | 0.26 | | |
| Prothrombin G20210A heterozygous | 68 | 18.8 8.2 | 2 | 12.0 0 | 0.12 | 0.112 | 89 | 18.3 8.1 | 2 | 12.0 0 | 0.13 | | |
| 677TT MTHFR genotype | 61 | 18.9 8.5 | 9 | 15.6 4.5 | 0.58 | 0.50 | 79 | 18.4 8.5 | 12 | 16.5 5.0 | 0.42 | | |
| HPA – 1b- positive † | 55 | 18.1 7.8 | 15 | 19.8 9.6 | 0.79 | 0.67 | 71 | 18.1 7.9 | 20 | 18.3 8.9 | 0.89 | | |
| α2807TT genotype | 59 | 19.2 8.6 | 11 | 14.5 4.0 | 0.095 | 0.09 | 79 | 18.4 8.2 | 12 | 16.4 7.8 | 0.21 | | |

* Multivariate analysis: including age, factor V Leiden, prothrombin G20210A mutation, 677TT MTHFR genotype, HPA-1b allele, and α2807TT genotype.

† Subjects with the HPA-1a/HPA-1a genotype were classified as HPA-1b-negative and subjects with the HPA-1a/HPA-1b genotype or HPA-1b/HPA-1b genotype were classified as HPA-1b-positive.

Women with late fetal loss

There was no significant association of any genetic risk factor with premature fetal loss in the subgroup analysis of women with at least one late miscarriage (≥ 12 weeks gestation), neither in the evaluation of the earliest fetal loss nor in the evaluation of all late fetal losses using the mixed model (Table 3).

Discussion

This study demonstrates a significant association of the $\alpha_2 807TT$ genotype of the platelet membrane integrin $\alpha_2\beta_1$ with premature onset of early fetal loss. Furthermore, our study confirms previous findings indicating an association of factor V Leiden, a risk factor for venous thrombosis, with late fetal loss (14).

The number of platelet $\alpha_2\beta_1$ receptor copies varies up to 10-fold among normal individuals, whereas the levels of other integrins do not (27–29). Three allelic differences in the α_2 gene are associated with expression levels on the $\alpha_2\beta_1$ integrin on the platelet surface: allele 1 (807T/837T/873A/Br^b), abbreviated $\alpha_2 807T$, is associated with increased levels of $\alpha_2\beta_1$, allele 2 (807C/837T/873G/Br^b) and allele 3 (807C/837C/873G/Br^a), abbreviated $\alpha_2 807C$, are each associated with lower levels of $\alpha_2\beta_1$ (27). The rate of platelet adhesion to collagen is proportional to the density of $\alpha_2\beta_1$ receptor copies on the platelet surface (27). Because $\alpha_2\beta_1$ mediates platelet adhesion to collagen *in vivo*, variation in its expression levels has a significant impact on platelet function, contributing to an increased risk of thrombosis or to bleeding (30).

In accordance with evidence of a prothrombotic phenotype for the $\alpha_2 807T$ allele, the results of our study have several major implications: First, since the $\alpha_2 807TT$ genotype is not related to fetal loss itself, as shown in the case-control design (Table 1), premature onset of early fetal loss can be explained by an effect associated with this genotype modulating the course of the underlying disease process. Thus, the $\alpha_2 807TT$ genotype appears to be a risk factor for premature onset of fetal loss in patients with already existing fetomaternal malfunction, but not a risk factor for the development of the disease *per se*. In contrast to the $\alpha_2 807TT$ genotype, factor V Leiden shows an increased odds ratio for late fetal loss, indicating an increased rate of fetal loss associated with this risk determinant (Table 1).

Placental vascular growth begins as early as 21 days post conception and continues throughout gestation. Disturbances in

the placental vascular development are associated with fetal loss in pregnancy (31). The pathomechanisms of early and late fetal loss comprise placental vascular abnormalities, imposing primarily as endothelial inflammation, and thrombotic occlusion of the placental vasculature (9, 32, 33). Since endothelial dysfunction can act as a major stimulus of hemostasis, it is likely that a risk determinant of thrombogenicity will be without consequence in regular non-altered vessels. Comparing cases with vascular alterations and controls who do not have vascular alterations will identify risk determinants associated with the disorder itself, but not risk determinants of thrombogenicity leading to premature fetal loss.

Second, the different results for early and late fetal loss are possible indicators for distinct pathophysiological mechanisms. The increased risk for late fetal loss associated with factor V Leiden, a risk determinant for venous but not for arterial thrombosis, may indicate vascular placental occlusions primarily located in the venous system. In contrast, the association of the $\alpha_2 807TT$ genotype, a potential risk determinant for arterial thrombotic occlusion, with premature early fetal loss may indicate vascular placental occlusions primarily located in the arterial system.

Considering the small sample size, our positive results for an association of the $\alpha_2 807TT$ genotype with premature early fetal loss needs confirmation in further studies. Moreover, we cannot rule out, that a significant association with the other genotypes might be observed in a larger study.

Possibly the $\alpha_2 807TT$ genotype is linked to another yet unidentified genetic marker, which represents the true risk determinant. Furthermore, it may be the case that cellular sources other than platelets are being affected, since the integrin $\alpha_2\beta_1$ also serves as a collagen receptor on fibroblasts and possibly other cells involved in early fetal development (34, 35).

If the $\alpha_2 807TT$ genotype-associated premature fetal loss is induced by an increased platelet thrombogenicity, our results may have implications in terms of the therapy with antiplatelet agents. The modulating influence of the $\alpha_2 807TT$ genotype on the onset of early fetal loss indicates that a platelet-dependent pathomechanism may be involved. Consequently, it will be of importance to examine whether the critical subgroup of patients could benefit from prevention therapy with a specific single or combined antiplatelet agents.

References

1. Preston FE, Rosendaal FR, Walker ID, et al. Increased fetal loss in women with heritable thrombophilia. *Lancet* 1996; 348: 913–6.
2. Roberts JM, Taylor RN, Musci TJ, et al. Preeclampsia: an endothelial cell disorder. *Am J Obstet Gynecol* 1989; 161: 1200–4.
3. Salafia CM, Pezzullo JC, Lopez-Zeno JA, et al. Placental pathologic features of preterm preeclampsia. *Am J Obstet Gynecol* 1995; 173: 1079–105.
4. Shanklin DR, Sibai BM. Ultrastructural aspects of preeclampsia. I. Placental bed and uterine boundary vessels. *Am J Obstet Gynecol* 1989; 161: 735–41.
5. Khong TY, Pearce JM, Robertson WB. Acute atherosis in pre-eclampsia: maternal determination and fetal outcome in the presence of the lesion. *Am J Obstet Gynecol* 1987; 157: 360–3.
6. Salafia CM, Minior VK, Pezzullo JC, et al. Intra-uterine growth restriction in infants of less than thirty-two weeks' gestation: associated placental pathologic features. *Am J Obstet Gynecol* 1995; 173: 1049–57.
7. Green JR. Placental previa and abruptio placentae. In: Creasy RK, Resnik R, ed. *Maternal Fetal Medicine: Principles and Practice*. Philadelphia. WB Saunders; 1994: 609–19.
8. Infante-Rivard C, David M, Gauthier R, et al. Lupus anticoagulants, anticardiolipin antibodies and fetal loss. *N Engl J Med* 1991; 325: 1063–6.
9. Rai R. Is miscarriage a coagulopathy? *Curr Opin Obstet Gynecol* 2003; 15: 265–8.
10. Rushton DI. Placental pathology in spontaneous miscarriage. In: Beard RW and Sharp F (eds) *Early pregnancy loss: mechanisms and treatment*. RCOG, London 1988 pp. 149–58.
11. Gris JC, Quere I, Monpeyroux F, et al. Case-control study of the frequency of thrombophilic disorders in couples with late fetal loss and no thrombotic antecedent- the Nimes Obstetricians and Haematologists Study 5 (NOHA 5). *Thromb Haemost* 1999; 81: 891–9.
12. Rai RS, Regan L, Hitolice A et al. Placental thrombosis and second trimester miscarriage in association

with activated protein C resistance. *Brit J Obstet Gynecol* 1996; 103: 842–4.

13. Younis JS, Ohel G, Brenner B, et al. Familial thrombophilia – the scientific rationale for thromboprophylaxis in recurrent pregnancy loss? *Hum Reprod* 1997; 12: 1389–90.

14. Kupferminc MJ, Eldor A, Steinmann N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. *N Engl J Med* 1999; 340: 9–13.

15. Rey E, Kahn SR, David M, et al. Thrombophilic disorders and fetal loss: a meta-analysis. *Lancet* 2003; 361: 901–8.

16. Bray PF. Platelet glycoprotein polymorphisms as risk factors for thrombosis. *Curr Opin Hematol* 2000; 7(5): 284–9.

17. Zotz RB, Scharf RE. Platelet receptor polymorphism and their role in cardiovascular disease. *J Lab Med* 2002; 26: 584–93.

18. Zotz RB, Winkelmann BR, Nauck M, et al. Polymorphism of platelet membrane glycoprotein IIIa: human platelet antigen 1b (HPA-1b/PLA2) is an inherited risk factor for premature myocardial infarction in coronary artery disease. *Thromb Haemost* 1998; 79(4): 731–5.

19. Vijayan KV, Goldschmidt-Clermont PJ, Roos C, et al. The PL(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions. *J Clin Invest* 2000; 105(6):793–802.

20. He L, Pappan K, Grenache DG, et al. The contribution of the $\alpha_2\beta_1$ integrin to vascular thrombosis in vivo. *Blood* 2003; 102: 3652–7.

21. Goodall AH, Curzen N, Panesar M, et al. Increased binding of fibrinogen to glycoprotein IIIa-proline33 (HPA-1b, PLA2, Zwb) positive platelets in patients with cardiovascular disease. *Eur Heart J* 1999; 20(10): 742–7.

22. Ridker PM, Hennekens CH, Lindpaintner K, et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. *N Engl J Med* 1995; 332: 912–7.

23. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3' untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. *Blood* 1996; 88: 3698–703.

24. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease in methylenetetrahydrofolate-reductase. *Nat Genet* 1995; 10: 111–3.

25. Unkelbach K, Kalb R, Santoso S, et al. Genomic RFLP typing of human platelet alloantigens Zw(PLA), Ko, Bak and Br (HPA-1, 2, 3, 5). *Br J Haematol* 1995; 89(1): 169–76.

26. Corral J, Rivera J, Gonzalez-Conejero R, et al. The number of platelet glycoprotein Ia molecules is associated with the genetically linked 807 C/T and HPA-5 polymorphisms. *Transfusion* 1999; 39(4): 372–8.

27. Littell R, Milliken GA, Stroup WW, et al. SAS system for mixed models. SAS Institute Inc., Cary (USA) 1999

28. Kritzik M, Savage B, Nugent DJ, et al. Nucleotide polymorphisms in the alpha2 gene define multiple al-

leles that are associated with differences in platelet alpha2 beta1 density. *Blood* 1998; 92: 2382–8.

29. Kunicki TJ, Orzechowski R, Annis D, et al. Variability of integrin alpha 2 beta 1 activity on human platelets. *Blood* 1993; 82: 2693–703.

30. Kunicki TJ, Kritzik M, Annis DS, et al. Hereditary variation in platelet integrin alpha 2 beta 1 density is associated with two silent polymorphisms in the alpha 2 gene coding sequence. *Blood* 1997; 89: 1939–43.

31. Di Paola J, Federici AB, Mannucci PM, et al. Low platelet $\alpha_2\beta_1$ levels in type I von Willebrand disease correlate with impaired platelet function in a high shear stress system. *Blood* 1999; 93: 3578–82.

32. Zygmunt M. Placental circulation: Clinical significance. *Early Pregnancy* 2001; 5(1): 72–3.

33. Kwak JY, Beer AE, Kim SH, et al. Immunopathology of the implantation site utilizing monoclonal antibodies to natural killer cells in women with recurrent pregnancy losses. *Am J Reprod Immunol* 1999; 41: 91–8.

34. Emmrich P, Seifert U. Pathologic-anatomic findings in spontaneous abortion and induced abortion during the 2nd pregnancy trimester. *Zentralbl Allg Pathol* 1990; 136(5): 411–8.

35. Elices MJ, Hemler ME. The human integrin VLA-2 is a collagen receptor on some cells and a collagen/laminin receptor on others. *Proc Natl Acad Sci USA* 1989; 86: 9906–10.

36. Kirchhofer D, Languino LR, Ruoslahti E, et al. Alpha 2 beta 1 integrins from different cell types show different binding specificities. *J Biol Chem* 1990; 265: 615–8.